Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference5%
- Check23 days agoChange DetectedThe page now shows a new version (v3.1.0) and includes a contact/identifier entry, while the old version reference (v3.0.2) is removed.SummaryDifference0.1%
- Check38 days agoChange DetectedUpdated from v3.0.1 to v3.0.2 and removed the 'Back to Top' control.SummaryDifference0.3%
- Check45 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.3%
- Check52 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name, location details, and specific drug information for Fruquintinib, HMPL-013, and sintilimab, while removing extensive disease categories and previous location terms.SummaryDifference3%
- Check67 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.